Asia PacificENPublic drug registration overview
Malaysia Pharmaceutical Registration Pathway
Public Summary Who this is for: Foreign holders and local applicants preparing to register new drugs, generics, biologics, health supplements, or natural products in Malaysia. Regu...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: Malaysia Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulator: National Pharmaceutical Regulatory Agency (NPRA), with requirements commonly anchored in the DRGD, product classification, local applicant responsibility, and post-market duties.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Public Summary
- Who this is for: Foreign holders and local applicants preparing to register new drugs, generics, biologics, health supplements, or natural products in Malaysia.
- Regulator: National Pharmaceutical Regulatory Agency (NPRA), with requirements commonly anchored in the DRGD, product classification, local applicant responsibility, and post-market duties.
- Access pathway: Classify the product and run a dossier gap assessment before preparing CTD/local materials for the applicable new-drug, generic, biologic, or other product route.
- Key risks: Local-applicant control, GMP/CPP consistency, BE or clinical evidence sufficiency, label and package-insert localisation, pharmacovigilance, and lifecycle variation maintenance.
Market Overview
- Market profile: Malaysia has a clear regulatory system and supports layered entry for new drugs, generics, biologics, health supplements, and natural products.
- Regulatory maturity: Medium-high. NPRA publishes the DRGD, covering registration process, quality control, inspection and licensing, and post-registration activities.
- Core decision: Classify the product first as a new drug, generic, biologic, health supplement, natural product, or interphase product, then follow DRGD requirements.
Regulator
- Authority: National Pharmaceutical Regulatory Agency (NPRA)
- Legal framework: Sale of Drugs Act 1952, Control of Drugs and Cosmetics Regulations 1984, and related laws
- Main guidance: Drug Registration Guidance Document (DRGD)
Product Types and Review Pathways
| Type | Main guidance | Focus |
|---|---|---|
| New drug | DRGD Appendix 3 | Full quality, safety, and efficacy evidence |
| Biologic | DRGD Appendix 4 | Biologic quality, comparability, and clinical evidence |
| Generic | DRGD Appendix 5 | Quality, BE, reference product, and labeling |
| Health supplement / natural product | Relevant DRGD appendices | Boundary classification is critical |
Official Sources and Verification Date
- NPRA official site: https://www.npra.gov.my/
- NPRA Drug Registration Guidance Document (DRGD): https://www.npra.gov.my/index.php/en/drug-registration-guidance-documents-drgd-e-book
- NPRA product registration FAQ: https://www.npra.gov.my/support/knowledgebase.php?article=3
- Verification date: 2026-05-10
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.